Or browse groups, people, or influence networks.
International AIDS Vaccine Initiative
The International AIDS Vaccine Initiative is a global not-for-profit, public-private partnership working to accelerate the development of vaccines to prevent HIV infection and AIDS.
At-A-Glance
Type: Non-profit, 501(c)(3)
Issue Areas: Healthcare Policy
Location: New York, NY View on map
Tax ID: 13-3870223
Most Recent Filing: 2024
Budget (2024): Assets: $129,852,638 Revenue: $131,181,475 Expenses: $143,043,595
The International AIDS Vaccine Initiative is a global not-for-profit, public-private partnership working to accelerate the development of vaccines to prevent HIV infection and AIDS.
Financial Statistics
Total Assets
Total Revenue
Total Expenses
Revenue Detail
Expenses Detail
Employee Compensation
- Number of Employees: 260
Highest Earning Employees
| Employee | Title | Total Compensation |
|---|---|---|
| Mark B Feinberg | PRESIDENT/CEO | $718,500 |
| Ana Cespedes Montoya | CHIEF OPERATING OFFICER | $552,506 |
| Dagna Laufer | VP AND HEAD OF CLINICAL DEVELOPMENT | $402,844 |
| Swati Gupta | VP, HEAD OF EID AND EPIDEMIOLOGY | $402,341 |
| Sangeetha Sagar | VICE PRESIDENT, PDC | $384,858 |
| Marion Gruber | VP, PUBLIC HEALTH & REG. SCIENCE | $383,236 |
| Christopher Parks | ASS. VP, VIRAL VACC. & HEAD OF DDL | $380,753 |
| Min Ding | GENERAL COUNSEL/BOARD SECRETARY | $368,570 |
| Mario Gagliano | CHIEF PEOPLE OFFICER, VP OF HR | $364,310 |
| Louis D Schwartz | ASST. SEC., CHIEF FIN. & ADMIN OFF. | $353,545 |
| Brandon Saft | DEPUTY CHIEF FINANCIAL OFFICER | $255,811 |
Grant Activity
All-time grants received statistics from Candid dataset:
- Total Grant Value: $593,668,775
- Number of Grants: 205
- Number of Funders: 60
Selection of highest value grants received from the last seven years:
| Amount | Year | Funder | Subject |
|---|---|---|---|
| $25,000,000 | 2021 | Gates Foundation | to develop a prophylactic vaccine against HIV |
| $24,531,681 | 2020 | Gates Foundation | to support the preparation of clinical materials, execution of toxicology studies and data analyses for CAVD investigators towards development of an HIV/AIDS vaccine |
| $21,685,896 | 2020 | Gates Foundation | to advance the CAVD-supported projects through the translational stage and into clinical evaluation, ultimately resulting in successful new HIV/AIDS interventions |
| $15,000,000 | 2023 | Gates Foundation | To conduct a proof-of-concept efficacy trial of the novel tuberculosis vaccine candidate, MTBVAC, in adolescents and adults in high tuberculosis burden countries. |
| $13,935,218 | 2022 | Gates Foundation | to identify and develop alternative biologics for the prevention and treatment of COVID-19 for low and middle income countries |
| $9,857,997 | 2024 | The Scripps Research Institute | GRANTS FOR SCIENTIFIC RESEARCH |
| $9,765,755 | 2025 | Gates Foundation | To develop a safe and effective HIV vaccine that will be accessible and affordable for those most at risk in LMICs. |
| $8,917,467 | 2021 | The Scripps Research Institute | GRANTS FOR SCIENTIFIC RESEARCH |
| $8,345,588 | 2024 | Gates Foundation | HIV |
| $7,216,413 | 2022 | The Scripps Research Institute | GRANTS FOR SCIENTIFIC RESEARCH |
| $5,526,666 | 2020 | The Wellcome Trust | Long-standing global health challenges like antimicrobial resistance (amr) require synergistic approaches to dramatically reduce global morbidity and mortality levels. We think that the availability of antimicrobial monoclonal antibodies (mabs), which can be used as a complementary strategy for vaccines, holds great promise for ameliorating the expansion of amr. A major challenge for the uptake of such antibody interventions by those most vulnerable to amr in low- and middle-income countries (lmics) is the associated costs of mabs. This proposal is focused on two major themes. First, we are proposing a portfolio approach to ab discovery and development for enteric bacteria with a focus on cross-reactive mabs that enable broad spectrum use to obviate the need for an accompanying diagnostic. This portfolio approach includes the optimization and development of an existing lead mab as well as screening cohorts to discover new antibodies for different enteric bacteria. The second theme is to set up a pipeline for ab optimization to improve antibody bactericidal potency, cross-reactivity to different enteric bacteria, ab half-life, and manufacturability to reduce cost of goods associated with an ab intervention. These approaches are meant to, respectively, reduce dosage requirements, enable broad spectrum use, reduce administration frequency, and increase the probability of success of advancing lead abs through manufacturing and process development. Iavi and partners think that investing in these two themes will greatly expedite the likelihood of advancing an effective ab intervention to address amr and the burden of diarrheal disease caused by enteric bacteria. |
| $4,999,512 | 2020 | Gates Foundation | to discover and develop HIV vaccine using platform mRNA technology |
| $4,500,000 | 2024 | Gates Foundation | HIV |
| $4,200,000 | 2024 | Gates Foundation | HIV |
| $4,130,787 | 2021 | Gates Foundation | to identify and develop alternative biologics for the prevention and treatment of COVID-19 for low and middle income countries |
| $3,732,638 | 2021 | The Wellcome Trust | This proposal aims to ultimately reduce global levels of morbidity and mortality from snakebite envenoming by discovering and developing antibodies that can neutralize the low molecular weight snake venom toxins – key contributors to the disease. These non-immunogenic toxins are poorly neutralized by currently available antivenoms produced by animal derived immunizations. This proposed project will discover neutralizing antibodies through immunization experiments using rationally designed immunogens and select for high-affinity antibodies via synthetic libraries using recombinant toxins. . |
| $3,157,576 | 2023 | The Scripps Research Institute | GRANTS FOR SCIENTIFIC RESEARCH |
| $3,117,095 | 2021 | The Wellcome Trust | The need for vaccines against invasive non-typhoidal salmonella (ints) is now increasingly being recognized, but there is no ints vaccine available for use in humans. Several potential candidate vaccines against ints are being developed. Vaccine development considerations include a bivalent ints vaccine (typhimurium and enteritidis) or possibly a trivalent vaccine (typhi/ints). Such financial investments not only need public-private partnerships, but also demand economic and public health justification. The world health organization (who) and other global partners have recently highlighted the need to justify investments in vaccines from a multi-stakeholder perspective. The overall objective of this project is to develop a full value of vaccine assessment (fvva) to understand the value of investment in an ints vaccine from a multi-stakeholder perspective. The long-term goal of this proposal is to pave the way for the development of a safe and efficacious ints vaccine, in-country licensure (marketing authorization in the country of manufacture), any necessary policy recommendations from the who strategic advisory group of experts (sage) on immunization, who prequalification (PQ), gavi financing, unicef purchasing and national technical advisory groups recommendations for vaccine use. This will be achieved as a joint ivi/who leadership and collaboration through a consensus process in partnership with multiple stakeholders.. |
| $2,960,342 | 2022 | Family Health International Inc | HIV/ AIDS PREVENTION |
| $2,249,057 | 2020 | National Institutes of Health | Pushing the envelope: optimizing vaccine display of flexibly linked HIV env trimer immunogens |
| $2,014,883 | 2023 | Gates Foundation | to produce a GMP lot of SMNP for use by BMGF grantees and partners to support the development of global health vaccines. |
| $1,900,000 | 2024 | Gates Foundation | DISCOVERY AND TRANSLATIONAL SCIENCES |
| $1,850,141 | 2024 | Gates Foundation | HIV |
| $1,565,097 | 2024 | Gates Foundation | DISCOVERY AND TRANSLATIONAL SCIENCES; VACCINE DEVELOPMENT |
| $1,439,900 | 2025 | Gates Foundation | To support HIV and TB vaccine advocacy and resource mobilization in European donor countries |
All-time grants given statistics from Candid dataset:
- Total Grant Value: $153,937,319
- Number of Grants: 264
- Number of Recipients: 60
Selection of highest value grants given from the last seven years:
| Amount | Year | Funder | Subject |
|---|---|---|---|
| $5,178,000 | 2024 | Multiple Sub-Saharan Africa Recipients | RESEARCH & DEVELOPMENT |
| $4,146,817 | 2021 | Multiple Europe Recipients | VACCINE ADVOCACY, PUBLIC AFFAIRS AND POLICY |
| $4,145,586 | 2024 | Multiple Sub-Saharan Africa Recipients | RESEARCH & DEVELOPMENT |
| $3,396,423 | 2022 | Multiple Sub-Saharan Africa Recipients | RESEARCH & DEVELOPMENT |
| $3,186,672 | 2023 | Multiple Europe Recipients | VACCINE ADVOCACY, PUBLIC AFFAIRS AND POLICY |
| $3,088,050 | 2023 | The Scripps Research Institute | RESEARCH & DEVELOPMENT |
| $2,839,575 | 2020 | The Scripps Research Institute | RESEARCH & DEVELOPMENT |
| $2,739,912 | 2024 | The Scripps Research Institute | RESEARCH & DEVELOPMENT |
| $2,550,777 | 2021 | The Scripps Research Institute | RESEARCH & DEVELOPMENT |
| $2,465,947 | 2023 | Multiple Sub-Saharan Africa Recipients | RESEARCH & DEVELOPMENT |
| $2,424,513 | 2022 | Multiple Sub-Saharan Africa Recipients | RESEARCH & DEVELOPMENT |
| $2,385,977 | 2022 | Texas Biomedical Research Institute | RESEARCH & DEVELOPMENT |
| $2,237,763 | 2024 | Multiple EUROPE (INCLUDING ICELAND & GREENLAND) Recipients | VACCINE ADVOCACY, PUBLIC AFFAIRS AND POLICY |
| $2,226,026 | 2023 | Multiple Sub-Saharan Africa Recipients | RESEARCH & DEVELOPMENT |
| $2,185,116 | 2020 | Multiple Europe Recipients | VACCINE ADVOCACY, PUBLIC AFFAIRS AND POLICY |
| $2,170,733 | 2021 | Multiple Sub-Saharan Africa Recipients | REARCH & DEVELOPMENT |
| $1,919,604 | 2020 | Multiple Europe Recipients | RESEARCH & DEVELOPMENT |
| $1,797,843 | 2022 | Multiple Sub-Saharan Africa Recipients | RESEARCH & DEVELOPMENT |
| $1,703,890 | 2022 | Multiple Europe Recipients | VACCINE ADVOCACY, PUBLIC AFFAIRS AND POLICY |
| $1,689,071 | 2022 | The Scripps Research Institute | RESEARCH & DEVELOPMENT |
| $1,667,115 | 2023 | Texas Biomedical Research Institute | RESEARCH & DEVELOPMENT |
| $1,548,272 | 2021 | Multiple Sub-Saharan Africa Recipients | RESEARCH & DEVELOPMENT |
| $1,539,027 | 2023 | Multiple Sub-Saharan Africa Recipients | RESEARCH & DEVELOPMENT |
| $1,528,321 | 2021 | Multiple Europe Recipients | RESEARCH & DEVELOPMENT |
| $1,505,477 | 2021 | Multiple Sub-Saharan Africa Recipients | RESEARCH & |
Contact InfluenceWatch to report errors, suggest edits, or provide tips for additional profiles.
Financials, employee compensation, and grant information provided by Candid.